ssflxl
![]()
Posts:204
Dear All
At least some positive news -
"The second-line administration of ramucirumab in combination with docetaxel has shown a statistically significant improvement in overall survival (OS) and progression-free survival (PFS) compared with placebo plus docetaxel in patients with non-small cell lung cancer (NSCLC), - See more at: http://www.onclive.com/web-exclusives/Ramucirumab-Combination-Improves-…
#sthash.xTVv0svx.dpuf"
ssflxl
Forums
Reply # - February 19, 2014, 09:56 PM
Reply To: ramucirumab
Yes definitely encouraging. We need to see the actual results, but knowing it came back as a positive result should leave us very hopeful. I'll share details as I learn of them.
-Dr. West
Reply # - February 19, 2014, 10:09 PM
Reply To: ramucirumab
Dr. West
Thanks. In this article, it sounds like they are ready to apply for FDA approval later this year. So they must have some solid data to be this confident.
thanks
ssflxl
Reply # - February 20, 2014, 05:59 PM
Reply To: ramucirumab
Yes I believe a similar result was just reported in gastric cancer, using paclitaxel instead of docetaxel.